Organogenesis Holdings Inc. Class A Common Stock (ORGO)
Organogenesis Holdings Inc. Class A (ORGO) is a biotechnology company focused on developing and commercializing advanced regenerative medicine products. It specializes in tissue repair and wound management solutions derived from living cells and biological materials, aiming to improve outcomes in diverse medical fields such as surgical, wound care, and dental applications.
Company News
DJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.
Organogenesis reported mixed results for its ReNu knee osteoarthritis treatment in a second Phase 3 trial, showing numerical improvement in pain reduction but not meeting the primary statistical endpoint. The company plans to request a pre-BLA meeting with the FDA to discuss potential approval.
Organogenesis Holdings Inc. reported strong Q4 2024 revenue growth of 27%, driven by better-than-expected customer demand. However, the company expects a challenging operating environment in the first half of 2025 due to delays in the implementation of new Medicare coverage policies for skin substitute products. The company provided financial gui...
Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts say these are penny stocks to "buy" but do you agree? The post 7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.